02:24 AM EDT, 08/24/2026 (MT Newswires) -- GSK (GSK.L) said Monday that the US Food and Drug Administration accepted for priority review its supplemental biologics license application for Jemperli, or dostarlimab, as a treatment for advanced rectal cancer. The application is specific to the administration of the treatment to patients with previously untreated stage II and III mismatch repair deficient locally advanced rectal cancer. The UK-based pharmaceutical company supported the application with results from the phase 2 Azur-1 trial. The Prescription Drug User Fee Act action date was set for February 2027, with a possibility for an earlier decision due to eligibility for expedited review under the National Priority Voucher program.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.